BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34708131)

  • 1. Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.
    Wang L; Wang Y; Wang J; Li L; Bi J
    J Immunol Res; 2021; 2021():3236384. PubMed ID: 34708131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    Chen F; Wang Q; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
    Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
    Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
    Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
    Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
    Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
    Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
    Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis.
    Zhu YD; Lu MY
    Mol Med Rep; 2018 Sep; 18(3):3403-3410. PubMed ID: 30066919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer.
    Wang L; Wang Y; Bi J
    Funct Integr Genomics; 2022 Oct; 22(5):797-811. PubMed ID: 35896848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer.
    Zhang P; Liu Z; Wang D; Li Y; Xing Y; Xiao Y
    Front Immunol; 2021; 12():724541. PubMed ID: 34512654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an autophagy-related gene signature that can improve prognosis of hepatocellular carcinoma patients.
    Huo X; Qi J; Huang K; Bu S; Yao W; Chen Y; Nie J
    BMC Cancer; 2020 Aug; 20(1):771. PubMed ID: 32807131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
    Lv J; Zhu Y; Ji A; Zhang Q; Liao G
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.